Navigation Links
Mylan Launches Innovative Portfolio of Antiretroviral Products for Treatment of HIV/AIDS in South Africa
Date:2/23/2013

JOHANNESBURG and PITTSBURGH, Feb. 23, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that its subsidiary in South Africa, Mylan (Proprietary) Limited, has launched a comprehensive portfolio of antiretroviral (ARV) products. South Africa has the world's largest HIV/AIDS population, with approximately 5.6 million1 people living with the disease and an estimated 1.7 million2 people receiving treatment.

Mylan's South African ARV portfolio initially will consist of 11 first- and second-line adult and pediatric regimens. Included are several innovative products, such as fixed-dose combinations, single blister "co-packs," heat-stable products and novel pediatric formulations that have been approved by the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO).

Mylan CEO Heather Bresch commented, "Mylan's mission is to provide the world's 7 billion people with access to high quality medicine. Recently, Mylan was awarded a 19% share of the ARV tender conducted by the South African government and we already have begun to deliver on this commitment. Building on this, today we are pleased to launch a broad and innovative ARV portfolio for the private sector. We believe that Mylan can set a new standard in the treatment of HIV/AIDS in South Africa by providing health care providers and those living with the disease access to high quality, affordable medicines."

Paul Miller , managing director and vice president of Mylan's South African business noted, "Mylan is an established leader in ARVs, with a global portfolio of 43 high quality ARVs, and the company has played a significant role in reducing the cost of these important therapies. The launch of Mylan's ARV portfolio in South Africa builds on our existing commercial presence in the country and is consistent with the company's commitment to addressing unmet needs with quality products. Mylan's ARV medicines are produced according to current Good Manufacturing Practices at facilities that have been inspected by leading regulatory authorities, including the South African Medicines Control Council, FDA and WHO. These quality standards are paramount everywhere that Mylan operates, including in South Africa."

Mylan has been a leading global player in the ARV arena for more than a decade. In 2002, Mylan Laboratories Limited (formerly Matrix Laboratories Limited) began providing reliable supplies of ARV active pharmaceutical ingredients to generic drug makers. In 2007, the company began offering finished dosage forms and launched a line of pediatric ARVs. Today, Mylan is widely respected for the quality, dependability and affordability of its ARVs. Mylan supplies ARVs to more than 120 countries around the world and nearly 40% of HIV/AIDS patients receiving treatment in developing countries depend on one of the company's ARV products.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which more than one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

[1] http://www.unaids.org/en/regionscountries/countries/southafrica/

[2] http://www.unaids.org/en/regionscountries/countries/southafrica/


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products
2. Mylan Schedules Fourth Quarter and Year End 2012 Financial Results Conference Call and Live Webcast
3. Mylan Appoints Melina Higgins and Rajiv Malik to Board of Directors
4. Mylan Announces Pricing of Senior Notes
5. Moodys and Standard & Poors Upgrade Mylan to Investment Grade Credit Ratings
6. Mylan Reports a 51% Increase in Third Quarter 2012 Adjusted Diluted EPS to $0.83
7. Mylan Selected as a Leading ARV Supplier to Indias National AIDS Control Organization
8. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
9. Mylan Launches Lithium Carbonate Extended-Release Tablets USP
10. Mylan Launches Commercial Operations in India, Starting with a Broad, Innovative Portfolio of ARV Products to Treat HIV/AIDS
11. Mylan Applauds Study Highlighting $1 Trillion in Savings for U.S. Health Care System Due to Generic Drugs Over Past Decade
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
(Date:1/19/2017)... FRANCISCO , January 19, 2017 The global  pacemaker ... new report by Grand View Research, Inc. The heightening prevalence of cardiac conditions ... the growth of Pacemaker globally. In addition, technological enhancements in these devices are ... ... Grand View Research Logo ...
(Date:1/19/2017)... , Jan. 18, 2017 The Global Therapy ... and access to partnering deals and agreements entered into ... in partnering deals - Top deals by value - ... development, technology type The report provides understanding and ... by the world,s leading healthcare companies. The report ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital media ... American Heart Association (AHA) to produce a three-part video series that uses humor to ... part of the launch of AHA’s Healthy For Good™ movement, which is designed to ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online plastic surgery community, ... to make it easier for their readers to get the information they desire. The ... well as the techniques used on those particular areas. , “We are excited to ...
(Date:1/19/2017)... ... January 19, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that it will be ... leader in innovative excipients and drug delivery solutions to health industries worldwide. The ...
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business ... new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba ... to facilitate a recapitalization of MedPro led by Harren Equity Partners. Brightwood ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... of a doctor who administered fillers that resulted in severe facial disfiguration. After ... was taken on by doctors at UCLA Medical Center, who removed the substances ...
Breaking Medicine News(10 mins):